Researchers identify target to help protect kidney patients' heart health

December 13, 2012

Blocking the receptor for proteins that constrict blood vessels reduces markers of heart-related problems in patients with chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings might be used to improve the health of patients with CKD, who most often die from cardiovascular disease.

Patients with CKD have an increased risk of developing , in part because kidney disease can cause their arteries to stiffen. This is thought to occur due to an impaired availability of a vasodilator—nitric oxide (NO)—in the blood. The protein endothelin-1 is a vasoconstrictor and opposes the actions of NO, suggesting that drugs that block its effects may help protect CKD patients' . One such drug is called sitaxentan, which blocks endothelin-1's receptor (called the ETA receptor).

Neeraj Dhaun, MD, PhD (University of Edinburgh, in Scotland) and his colleagues conducted a randomized, double-blind study in 27 patients with CKD to compare the effects of sitaxentan, nifedipine (a blood vessel relaxant), and placebo on , blood pressure, arterial stiffness, and various heart-related markers.

Among the major findings after six weeks of treatment:

  • Placebo and nifedipine did not affect three markers of heart-related problems: blood levels of uric acid; blood levels of asymmetric dimethylarginine (ADMA), a blocker of NO production; and urine levels of endothelin-1.
  • Sitaxentan treatment led to statistically significant reductions in all three of these markers.
  • Sitaxentan reduced proteinuria (an excess excretion of protein in the urine) to a significantly greater extent than nifedipine. Proteinuria is an indicator of .
  • Nifedpine and sitaxentan both reduced blood pressure to a similar extent.
"The current study shows, for the first time, that ETA receptor antagonism selectively lowers novel in patients with kidney disease independent of blood pressure. These effects were seen in patients already receiving optimal treatment," said Dr. Dhaun. "These findings suggest a potential role for ETA receptor antagonism in conferring additional longer-term cardiovascular and renal benefits in patients with kidney disease," he added.

Explore further: Study questions safety and effectiveness of common kidney disease drugs

More information: The article, entitled "Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD," will appear online: doi: 10.1681/2012040355

Related Stories

Kidney drugs hampered by high blood phosphate

August 18, 2011

High blood phosphate levels can set chronic kidney disease (CKD) patients on a rapid path to kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). To ...

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.